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Abstract
Background: Genetic variation may underlie phenotypic variation in chronic obstructive
pulmonary disease (COPD) in subjects with and without alpha 1 antitrypsin deficiency (AATD).
Genotype specific sub-phenotypes are likely and may underlie the poor replication of previous
genetic studies. This study investigated subjects with AATD to determine the relationship between
specific phenotypes and TNFα polymorphisms.
Methods: 424 unrelated subjects of the PiZZ genotype were assessed for history of chronic
bronchitis, impairment of lung function and radiological presence of emphysema and bronchiectasis.
A subset of subjects with 3 years consecutive lung function data was assessed for decline of lung
function. Four single nucleotide polymorphisms (SNPs) tagging TNFα were genotyped using
TaqMan® genotyping technologies and compared between subjects affected by each phenotype and
those unaffected. Plasma TNFα levels were measured in all PiZZ subjects.
Results: All SNPs were in Hardy-Weinberg equilibrium. A significant difference in rs361525
genotype (p = 0.01) and allele (p = 0.01) frequency was seen between subjects with and without
chronic bronchitis, independent of the presence of other phenotypes. TNFα plasma level showed
no phenotypic or genotypic associations.
Conclusion: Variation in TNFα is associated with chronic bronchitis in AATD.
Background
Chronic obstructive pulmonary disease (COPD) is
thought to be the result of environmental triggers in
genetically susceptible individuals. Although cigarette
smoking is the main environmental risk factor, only about
15% of smokers develop clinically significant disease[1],
suggesting other influences on disease expression. This is
supported by family studies showing ancestral aggrega-
tion of spirometric abnormalities both in the general pop-
ulation [2] and in relatives of patients with COPD [3].
Moreover, differences in rate of decline of lung function
between smokers[4] suggests a gene-environment interac-
tion.
COPD is associated with an abnormal inflammatory
response in which proteases[5] and oxidants[6] play a sig-
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important in systemic disease and associated co-morbidi-
ties[7]. Tumour necrosis factor alpha (TNFα) is an inflam-
matory cytokine which is elevated in the sputum[8],
bronchial biopsies[9] and circulation [10] of COPD
patients. The TNFα gene (TNFα) has been investigated in
several COPD phenotypes [11-14] but in general associa-
tions have been poorly replicated[13].
In AATD there is significant variation in the clinical phe-
notype. Although classically associated with basal pan-
lobular emphysema, it is now recognised that multiple
phenotypes typical of usual COPD occur, including cen-
trilobular emphysema, bronchitis and bronchiectasis
[15]. As in usual COPD other genetic influences may be
important in determining clinical features [16-19], but no
studies have examined the role of candidate genes in the
full range of COPD phenotypes. Since inflammation is
more marked in AATD than usual COPD [20], perhaps
driven by a key interaction between AAT and TNFα [21],
we hypothesised that variation in TNFα may influence
clinical phenotype in AATD.
Methods
Study design
In this case-control association study, cases comprised
subjects with AATD affected by a COPD phenotype and
those unaffected acted as AATD controls. Subjects were
genotyped for four tag single nucleotide polymorphisms
(SNPs) selected to cover common variation in TNFα. Gen-
otype and allele frequency were compared between cases
and controls, with adjustment for confounding variables
and phenotypic overlap. Plasma TNFα levels were com-
pared with SNP genotype.
Study subjects
Four hundred and twenty four unrelated Caucasian sub-
jects from the UK national registry for AATD were studied.
Ethical approval was given by the local ethics committee.
All patients had a serum alpha-1-antitrypsin (AAT) level
of <11 μM and PiZZ genotype confirmed by specific PCR
(Heredilab, Salt Lake City, USA). None of the subjects had
ever received AAT replacement.
Clinical phenotyping
A full clinical assessment including smoke exposure, pres-
ence of chronic bronchitis (defined as a productive cough
for at least 3 months of at least 2 consecutive years[22]),
lung function testing and high resolution CT scanning of
the chest was undertaken, as described previously [23].
Annual lung function measurement allowed assessment
of decline of FEV1. Linear regression was used to calculate
decline over 3 years, such that the slope of the line
between time zero and 3 years for each subject repre-
sented loss per year. The presence of bronchiectasis was
determined as described by Naidich et al [24] by a single
radiologist. The presence of emphysema was determined
by the appearance of the scan and density mask analysis
of slices at the level of the aortic arch (representing the
upper zone) and the inferior pulmonary vein (represent-
ing the lower zone) using a threshold of -910HU. This
threshold has been deemed optimal for emphysema
detection[25], and validated against physiological meas-
ures in AATD [26]. Patients whose voxel index exceeded
values seen in normal subjects in either zone[27] were
deemed to have emphysema.
Genotyping and TNFα quantification
SNPs to tag TNFα were chosen using linkage disequilib-
rium (LD) data for UK Caucasians [28], according to
established methods [29], revealing four tags needed to
capture all SNPs with minor allele frequency >0.05 using
a cut off of r2>0.8. DNA extraction was performed using a
modified Nucleon Bacc II kit (Tepnel Life Sciences, UK)
and quantified using Picogreen® (Molecular Probes Inc,
UK). Genotyping was carried out using TaqMan® genotyp-
ing technologies (Applied Biosystems, UK) on an
ABI7900 HT. All genotyping assays were pre-validated by
the suppliers, and all plates included appropriate negative
controls. Stable state plasma TNFα was measured using a
high sensitivity ELISA (R & D systems, Abingdon, UK) as
described previously [30].
Statistical Analysis
Deviation from Hardy Weinberg equilibrium was checked
for all SNPs. Data was analysed using SPSS (version 12,
November 2003, Chicago: SPSS Inc) and haplotype anal-
yses carried out in Haploview[31]. Comparisons of demo-
graphic and clinical features between subgroups were
carried out using the Mann Whitney or t-tests, as appropri-
ate. Genotype and allele frequency of each tag SNP was
compared between AATD subjects with and without
emphysema, bronchiectasis and chronic bronchitis using
logistic regression controlling for age, gender, smoke
exposure and presence of additional phenotypes. Qualita-
tive outcomes were chosen where possible since they may
be more informative in AATD[32]. Quantitative genetic
association analysis was carried out for FEV1, FEV1/FVC,
KCO, upper zone voxel index (UZVI) and lower zone
voxel index (LZVI) using general linear models, account-
ing for covariates as before. Analyses of HRCT measures
were only carried out in those with emphysema. Additive
models were assumed for all SNPs. Plasma TNFα level was
compared between genotypes for each associated SNP
using regression controlling for age; no other covariates
were significant in the models.Page 2 of 8
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Clinical phenotypes
The clinical features of the whole group and of those with
each sub-phenotype are shown in table 1. The frequency
of each qualitative phenotype within the subjects is
shown in figure 1a, and the degree of overlap between
them in figure 1b. Emphysematous subjects had smoked
more than those without (p < 0.001). There was no differ-
ence in smoke exposure, lung function or UZVI between
those with and without bronchiectasis, though affected
subjects were older (p < 0.001) and exhibited more severe
lower zone emphysema (p = 0.03). Subjects with chronic
bronchitis had lower FEV1 (p = 0.01) but no other demo-
graphic or clinical features differed. There were no gender
differences between those with and without each of the
qualitative phenotypes. The group assessed for decline of
lung function showed no difference in any demographic
or clinical features from the whole group, except that they
had smoked slightly more (p = 0.030).
In the regression models age remained a significant pre-
dictor of both emphysema and bronchiectasis (B = 0.09
and 0.05 respectively, both p < 0.0001), whilst pack years
smoked was associated with emphysema (B = 0.10, p <
0.0001). No demographic or clinical features predicted
the development of chronic bronchitis.
Genetic associations
Genotyping was successful in 95.3% of cases. All SNPs
were in Hardy Weinberg equilibrium. Allele frequencies
for each tag SNP are shown in table 2. A significant differ-
ence in allele frequency was seen between subjects with
and without chronic bronchitis for rs361525 (both p =
0.01), with the A allele conferring an odds ratio (OR) of
2.08 (95% confidence interval 1.18–3.67) in the regres-
sion analysis. In the regression analyses for presence of
emphysema and bronchiectasis no tag SNP made a signif-
icant contribution. There were no tag SNP associations
with lung function, emphysema severity or decline of
FEV1. No haplotypes were observed for analysis.
Plasma TNFα associations
Plasma TNFα was significantly correlated with age (r =
0.21, p = 0.05), but did not show any variation between
sub-phenotypes or correlation with disease severity as
measured by lung function or HRCT. A regression model
controlling for age did not show any association of
plasma level with rs361525 genotype, either in the whole
group or the subgroup with chronic bronchitis. Levels in
each sub-phenotype are shown in table 3.
Discussion
Our results show an association between the A allele of
rs361525 subjects and chronic bronchitis in AATD. One
previous study in COPD genetics has tagged TNFα[13]
but did not find an association with rs361525. Subjects
included a family cohort with airflow obstruction, and
cases with emphysema. No previous studies in COPD
have looked for association of chronic bronchitis with
rs361525.
The importance of chronic bronchitis has been recognised
by other COPD genetic association studies [14,33]. Its
definition has been standardised for many years in respi-
ratory medicine[22], but remains a historical definition,
thus prone to problems with patient recall. Nevertheless it
is an important phenotype to ascertain, as it may affect
patient management: mucolytics may be more appropri-
ate in the presence of a productive cough[34], and co-
existence with an HRCT diagnostic of bronchiectasis
might prompt addition of airway clearance measures. A
high incidence of HRCT changes suggestive of bron-
chiectasis is seen in patients with emphysema[35] and it
is not yet clear whether all such subjects should be man-
aged as aggressively as those with typical symptomatol-
ogy. Anti-TNF therapy has been disappointing in
COPD[36], but was not assessed specifically in chronic
bronchitis despite the importance of TNFα in the patho-
physiology of the condition[9]. Furthermore, response to
anti-TNF treatment may be dictated by TNFα geno-
type[37], perhaps indicating a need for further studies
directed to sub-phenotype or genotype.
Although there is a degree of overlap of COPD pheno-
types, our results are specific to chronic bronchitis, and
concur with prior evidence regarding a role for TNFα in
airways disease [9]. Such an association is lacking for pres-
ence or severity of parenchymal disease, defined by
emphysema on HRCT. This suggests different genetic
influences upon the development of each sub-phenotype
and supports the view that inadequate patient characteri-
sation may underlie poor replication of previous COPD
genetic association studies. It is also of interest that the
influence of age and smoke exposure differed between
COPD phenotypes in the regression models, further
emphasising differences in pathogenesis. Some markers
of disease, notably CT densitometry, can become abnor-
mal at or below the age of 20 in AATD[38], such that it
was important for us to include all adult PiZZ subjects in
our analyses. Despite maximising our numbers in this
way we were unable to show any TNFα effect on quanti-
tative phenotypes, again emphasising the specificity of
association with chronic bronchitis.
Our reported genetic association in AATD may be
explained by the interaction between TNFα and AAT.
TNFα release is suppressed by AAT in vitro[21] and in ani-
mal models[39]. Consequently, TNFα effects may be
more pronounced in AATD where this suppression is
reduced. These epistatic effects resulting from cytokinePage 3 of 8
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Table 1: Clinical features of the patient group. 
Whole group n = 
424
Decline group n = 
110
Emphysema Bronchiectasis Chronic bronchitis
Yes n = 279 No n = 70 Yes n = 83 No n = 266 Yes n = 159 No n = 265
Gender (% male) 59.91 66.36 64.16 54.29 57.83 63.67 64.78 57.03
Age (years) 50.01 (0.52) 51.48 (0.92) 51.76 (0.78) 41.52 (33.77–49.27) 54.18 (1.03) 48.90 (0.63) 50.79 (0.77) 49.48 (0.69)
Pack years 14.00(2.35–25.65) 18.75 (9.01–28.49) 17.50 (7.65–27.35) 0 (0–4.18) 14.63 (4.33–25.93) 13.50 (1.40–24.60) 14.63 (2.55–26.71) 12.75 (0.75–24.75)
FEV1 %predicted 37.15 (18.30–56.04) 35.01 (18.25–51.77) 32.08 (18.94–45.22) 102.88 (80.93–124.83) 36.64 (14.59–58.69) 35.54 (17.39–53.69) 32.76 (15.49–50.03) 38.17 (14.18–62.16)
FEV1/FVC 38.40 (25.95–50.85) 37.30 (27.10–48.40) 35.00 (26.00–44.00) 73.60 (63.10–84.10) 40.10 (24.35–55.85) 37.50 (25.00–48.00) 37.85 (26.85–48.85) 39.40 (26.40–52.40)
KCO %predicted 69.82 (1.18) 68.09 (2.12) 63.18 (1.38) 98.66 (2.55) 67.85 (2.75) 70.57 (1.54) 67.62 (2.31) 71.34 (1.89)
UZVI 31.09 (1.05) 32.84 (1.69) 32.71 (1.02) 2.31 (0.39) 33.45 (1.89) 30.63 (1.27) 32.98 (1.69) 29.88 (1.36)
LZVI 44.59 (1.21) 52.10 (38.53–65.68) 46.78 (1.14) 5.85 (1.01) 54.15 (39.50–68.80) 47.95 (32.15–63.75) 48.85 (34.60–63.10) 49.50 (31.90–67.10)
Decline of FEV1 
(ml/yr)
31.3 (4.1)
Data is presented as mean (SEM) or median (IQR) dependent on its distribution. UZVI = upper zone voxel index, LZVI = lower zone voxel index. The only significant difference between the decline group 
and the whole dataset was that they had smoked more (p = 0.01).
Respiratory Research 2008, 9:52 http://respiratory-research.com/content/9/1/52interactions have previously been reported in asthma in
which multiple polymorphisms in genes involved in the
Th2 immune response, rather than individual SNPs
appear to increase the risk of disease [40].
rs361525 (G-238A) is located in the promoter region of
TNFα and has been studied extensively in many different
disease states, although little evidence exists for a func-
tional effect. Cellular studies of TNFα promoter region
SNPs suggest that G-238A increases gene transcription
[41]. Conversely gene expression in patients with psoria-
sis (a disease with which the -238 A allele is strongly asso-
ciated[42]) appears reduced [43]. Further functional work
clarifying the role of rs361525 would be indicated if fine
mapping of the region surrounding it confirmed it to be
the functional variant associated with disease, rather than
merely a polymorphism in linkage disequilibrium. Such
studies are expensive, and alternative surrogate support
for a functional effect may be gained by assessing plasma
TNFα levels [44]. In the current study no association was
found between rs361525 genotype and plasma TNFα lev-
els. This may be because of the specific association with
airways disease since airway and plasma inflammatory
markers do not correlate in COPD [45]. However many
factors influence airway inflammation in COPD, includ-
ing bacterial colonisation[46] and cachexia [10] so any
study of genetic association with airway inflammatory
markers would require matching of subjects for these fea-
tures.
The TNFα promoter region is in strong LD with HLA class
II alleles in Caucasians [47], particularly between
rs1800629 and the HLA DR3 haplotype. This has not
been observed for rs361525, therefore it is unlikely that
our results are due to LD with HLA alleles.
The results reported in our study are without adjustment
for multiple statistical testing as corrections such as Bon-
ferroni appear overly conservative in genetic association
studies [48], hence are inappropriate. This is particularly
true when several theories are being tested, as in our study
in which we hypothesised that each SNP could be driving
any of three qualitative COPD phenotypes, or affecting
disease severity via several quantitative phenotypes. Statis-
tical significance has been proposed if it reaches the level
needed for a genome wide study (generally considered to
be p ≤ 5 × 10-5 [48]), or by replication in an independent
population. We have considered the latter approach: a
second small familial dataset does exist in the UK that
could act as a replication group. However, within this
dataset there is no difference in the prevalence of chronic
bronchitis between family members [49]. As such we
would be unable to test our hypothesis in this cohort.
These challenges are inherent in studying AATD, as
recruitment of datasets powered for genome wide signifi-
cance using healthy AATD controls may be impossible,
because of the high rates of disease phenotypes (see Figure
1a). International collaborations to create larger datasets
could certainly help overcome this problem although geo-
graphical variation of genes, particularly those within the
HLA region such as TNFα, may be a further confounding
factor [50].
Conclusion
The current study conducted on the UK national registry
of AATD presents data to indicate that variation in TNFα
influences phenotype in AATD. It further supports the
hypothesis that the range of COPD phenotypes may be
driven by specific underlying genetic susceptibilities in a
similar manner to usual COPD.
Table 2: Allele frequencies of tag SNPs. 
Minor Allele frequency (%) (OR, p value)
SNP [major allele, minor allele] All Chronic bronchitis Emphysema Bronchiectasis
rs1800629 [G, A] 21.73 24.32 21.97 26.58
rs361525 [G, A] 8.60 11.76 (2.08, 0.01) 8.24 5.00
rs1799964 [T, C] 25.32 26.69 25.10 26.58
rs3093662 [A, G] 8.91 11.33 8.17 4.55
Odds ratio (OR) and p value are given in parentheses for significant associations only.
Table 3: Plasma TNFα levels in AATD subjects. 
Plasma TNFα (pM)
All subjects 0.074 (0.004)
Emphysema 0.079 (0.005)
Bronchiectasis 0.089 (0.012)
Chronic bronchitis 0.078 (0.007)
Data is expressed as mean (SEM).Page 5 of 8
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